11.03.2026 • News

WeylChem Ceases Production at US Site, Appoints US Sales Director

WeylChem will discontinue production at its Elgin, USA site and has established a new US sales office led by Cameron Young, Sales and New Business Development Director.

Cameron Young
Cameron Young
© WeylChem

As part of a comprehensive review of its operational structure, WeylChem has decided to discontinue production at the Elgin site. The decision is based on changed market conditions and a strategic focus on the long-term sustainability of the global production structure.

The discontinuation of production activities at the Elgin site expressly does not mean a withdrawal from the US market. North America remains a strategically important market for WeylChem and customers will continue to be reliably supplied via the Group's international production network.

In this context, WeylChem has established a new US Sales Office, headed by Cameron Young, Sales and New Business Development Director. The team will focus on expanding existing customer relationships, developing new business opportunities and dovetailing closely with the WeylChem Group's global manufacturing network.

"The US remains a strategically important market for WeylChem, and by adapting our structure to current market conditions, we can continue to reliably serve our customers while ensuring our long-term competitiveness," said Benjamin Bechem, President of WeylChem CDMO.

WeylChem is working closely with employees and local partners to ensure a responsible and respectful transition.

Company

Logo:

WeylChem International GmbH

Alt-Fechenheim 34
60386 Frankfurt
Germany

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read